Surgery, hyperthermic chemoperfusion, and postoperative chemotherapy: The national cancer institute and washington hospital center experience

Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies

Volumn , Issue , 2005, Pages 732-754

  Carroll, Nancy M ^a   Mohamed, Faheez ^b   Sugarbaker, Paul H ^b   Alexander, H Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49849092335     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-28274-2_49     Document Type: Chapter

References (33)

1. Antman K, Pomfret F, Aisner J, et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983;1:386-386.
2. Cho H-K, Lush RM, Bartlett DL, et al. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 1999;39:1-8.
3. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol 2002;29(1):51-61.
4. Begossi G, Gonzalez-Moreno S, Ortega-Perez G, Fon LJ, Sugarbaker PH. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Eur J Surg Oncol 2002;28(1):80-87.
5. Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998;83:1251-1261.
6. Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999;6(6):582-590.
7. Ma GY, Bartlett DL, Reed E, et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 1997;3:174-179.
8. Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996;81:193-211.
9. Bartlett DL. Peritoneal carcinomatosis. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins, 2000:1-8.
10. Kerrigan SA, Turnnir RT, Clement PB, Young RH, Churg A. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 2002;94(2):378-385.
11. Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980;68:356-362.
12. Alexander HR Jr, Bartlett DL, Libutti SK. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In: Markman M, ed. Current Clinical Oncology: Regional Chemotherapy: Clinical Research and Practice. Totowa, NJ: Humana Press, 2000:127-150.
13. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg 1999;384:576-587.
14. Dikhoff T, van der Heider J, Dubbelman R, ten Bokkel Huinink WW. Tissue concentration of platinum after intraperitoneal cisplatin administration in patients (PTS). Proc AACR 1985;26:162.
15. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335(26):1950- 1955.
16. Sugarbaker PH, Sweatman TW, Graves T, Cunliffe WJ, Israel MA. Early postoperative intraperitoneal adriamycin. Reg Cancer Treat 1991;4:127-131.
17. Bruckner HW, Cohen CJ, Goldberg JD, et al. Improved chemotherapy for ovarian cancer with cis-diaminedichloroplatinum and Adriamycin. Cancer 1981;47(9):2288-2294.
18. Benoit L, Duvillard C, Rat P, Chauffert B. The effect of intra-abdominal temperature on the tissue and tumor diffusion of intraperitoneal cisplatin in a model of peritoneal carcinomatosis in rats. Chirurgie 1999;124(4):375-379.
19. Herman TS. Temperature dependence of Adriamycin, cis- diaminedichloroplatinum, bleomycin, and 1, 3-bis (2-chloroethyl)-1-nitrosourea cytotoxicity in vitro. Cancer Res 1983;43(2):517-520.
20. Takahashi I, Emi Y, Hasuda S, Kakeji Y, Maehara Y, Sugimachi K. Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors. Surgery 2002;131(1 suppl):S78-S84.
21. Zakris EL, Dewhirst MW, Riviere JE, Hoopes PJ, Page RL, Oleson JR. Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 1987;5:1613-1620.
22. Baba H, Maehara Y, Takeuchi H, Inutsuka S, Sugimachi K. Optimal scheduling increases therapeutic gain of Adriamycin combined with hyperthermia. Anticancer Res 1993;13(3):651-654.
23. Giovanella BC, Stehlin JS Jr, Morgan AC. Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res 1976;36:3944-3950.
24. Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res 1984;44:605-612.
25. Howell SB, Pfeifle CE, Wung WE. Intraperitoneal cisplatin with sodium thiosulfate protection. Ann Intern Med 1982;97:845-851.
26. Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma. Chest 1988;93:159-162.
27. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-153.
28. Sridhar KS, Doria R, Raub W A Jr, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992;70(12):2969-2979.
29. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;118(7):547-550.
30. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in South East England: clinicopathological experience of 272 cases. Thorax 1997;52(6):507-512.
31. Neumann V, Muller KM, Fischer M. [Peritoneal mesothelioma-incidence and etiology]. Pathologe 1999;20(3):169-176.
32. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999;70(1):6-12.
33. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67(10):999-1003.